INSULET CORP (PODD) Stock News

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

Discover the top S&P500 movers in Friday's pre-market session and stay informed about market dynamics.

Before the opening bell on Friday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.

Top S&P500 movers in Thursday's session

Top movers analysis one hour before the close of the markets of S&P500 on 2025-01-16: top gainers and losers in today's session.

Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session.

Which S&P500 stocks are moving on Thursday?

NASDAQ:PODD—A High-Growth Stock Gearing Up for Its Next Upward Move.

Is INSULET CORP (NASDAQ:PODD) on the Verge of a Major Breakout as a Strong Growth Stock?

Insulet Launches Revolutionary Omnipod® 5 in Five More Countries in Europe

Stryker Had A Good Year Last Year; Here's How It's Looking For 2025

Reflecting its strong growth, on Monday the Relative Strength (RS) Rating for Stryker stock got an upgrade from 70 to 74.

Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

Lantheus Stock Doubled In A Year Amid Wide Use Of Its AI-Enabled Medical Devices

Lantheus Holdings sees its Relative Strength Rating reach the 80-plus level.

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

Inari Medical Stock Gets RS Rating Upgrade

On Wednesday, Inari Medical stock received an upgrade to its Relative Strength (RS) Rating, from 65 to 72.

Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court

Novocure Stock Earns 96 RS Rating

On Tuesday, Novocure stock got a positive adjustment to its Relative Strength (RS) Rating to 96, up from 73.

Insulet Announces Omnipod® 5 System is Now Compatible with Abbott’s FreeStyle Libre 2 Plus Sensor in the U.S.

Insulet to Present at Upcoming Investor Conferences

Insulet Soars Out Of Buy Zone As 'Beat-And-Raise Cadence' Continues

Shares soared out of a buy zone after beating third-quarter forecasts and raising its outlook for 2024.

Insulet Reports Third Quarter 2024 Revenue Increase of 26% Year-Over-Year (25% Constant Currency1)

Insulet Announces Array of Activities to Support National Diabetes Awareness Month and World Diabetes Day in November

Omnipod® 5 App for iPhone® Now Fully Available in the United States

Solventum Stock Earns 81 RS Rating

Solventum stock saw a positive improvement to its Relative Strength Rating on Tuesday, with an upgrade from 78 to 81.